Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Bréchot C[au]:

Search results

Items: 1 to 50 of 457

1.

A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B.

Rossignol JF, Bréchot C.

Hepatol Commun. 2019 Mar 29;3(6):744-747. doi: 10.1002/hep4.1339. eCollection 2019 Jun.

2.

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.

Revill PA, Penicaud C, Brechot C, Zoulim F.

Genes (Basel). 2019 Apr 1;10(4). pii: E260. doi: 10.3390/genes10040260. Review.

3.

2018 international meeting of the Global Virus Network.

Brechot C, Bryant J, Endtz H, Garry RF, Griffin DE, Lewin SR, Mercer N, Osterhaus A, Picot V, Vahlne A, Verjans GMGM, Weaver S.

Antiviral Res. 2019 Mar;163:140-148. doi: 10.1016/j.antiviral.2019.01.013. Epub 2019 Jan 25. Review.

PMID:
30690044
4.

The hepatitis B epidemic and the urgent need for cure preparedness.

Lazarus JV, Block T, Bréchot C, Kramvis A, Miller V, Ninburg M, Pénicaud C, Protzer U, Razavi H, Thomas LA, Wallace J, Cowie BC.

Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):517-518. doi: 10.1038/s41575-018-0041-6. No abstract available.

PMID:
30050162
5.

Enteric Delivery of Regenerating Family Member 3 alpha Alters the Intestinal Microbiota and Controls Inflammation in Mice With Colitis.

Darnaud M, Dos Santos A, Gonzalez P, Augui S, Lacoste C, Desterke C, De Hertogh G, Valentino E, Braun E, Zheng J, Boisgard R, Neut C, Dubuquoy L, Chiappini F, Samuel D, Lepage P, Guerrieri F, Doré J, Bréchot C, Moniaux N, Faivre J.

Gastroenterology. 2018 Mar;154(4):1009-1023.e14. doi: 10.1053/j.gastro.2017.11.003. Epub 2017 Nov 11.

6.

Hepatitis C virus core protein targets 4E-BP1 expression and phosphorylation and potentiates Myc-induced liver carcinogenesis in transgenic mice.

Abdallah C, Lejamtel C, Benzoubir N, Battaglia S, Sidahmed-Adrar N, Desterke C, Lemasson M, Rosenberg AR, Samuel D, Bréchot C, Pflieger D, Le Naour F, Bourgeade MF.

Oncotarget. 2017 Apr 20;8(34):56228-56242. doi: 10.18632/oncotarget.17280. eCollection 2017 Aug 22.

7.

Diagnostic preparedness for infectious disease outbreaks.

Perkins MD, Dye C, Balasegaram M, Bréchot C, Mombouli JV, Røttingen JA, Tanner M, Boehme CC.

Lancet. 2017 Nov 11;390(10108):2211-2214. doi: 10.1016/S0140-6736(17)31224-2. Epub 2017 May 31.

PMID:
28577861
8.

Septin 9 induces lipid droplets growth by a phosphatidylinositol-5-phosphate and microtubule-dependent mechanism hijacked by HCV.

Akil A, Peng J, Omrane M, Gondeau C, Desterke C, Marin M, Tronchère H, Taveneau C, Sar S, Briolotti P, Benjelloun S, Benjouad A, Maurel P, Thiers V, Bressanelli S, Samuel D, Bréchot C, Gassama-Diagne A.

Nat Commun. 2016 Jul 15;7:12203. doi: 10.1038/ncomms12203.

9.

The Institut Pasteur International Network: a century-old global public health powerhouse.

Bréchot C.

Lancet. 2016 May 28;387(10034):2181-3. doi: 10.1016/S0140-6736(16)00744-3. Epub 2016 May 1. No abstract available.

PMID:
27145701
10.

Diagnostic Performance of Alpha-Fetoprotein, Protein Induced by Vitamin K Absence, Osteopontin, Dickkopf-1 and Its Combinations for Hepatocellular Carcinoma.

Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C.

PLoS One. 2016 Mar 17;11(3):e0151069. doi: 10.1371/journal.pone.0151069. eCollection 2016.

11.

A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases.

Nalpas B, Ichaï P, Jamot L, Carbonell N, Rudler M, Mathurin P, Durand F, Gerken G, Manns M, Trautwein C, Larrey D, Radenne S, Duvoux C, Leroy V, Bernuau J, Faivre J, Moniaux N, Bréchot C, Amouyal G, Amouyal P, Samuel D.

PLoS One. 2016 Mar 16;11(3):e0150733. doi: 10.1371/journal.pone.0150733. eCollection 2016.

12.

Train Africa's scientists in crisis response.

Bréchot C.

Nature. 2015 Aug 6;524(7563):7. doi: 10.1038/524007a. No abstract available.

PMID:
26245544
13.

Gamma-smooth muscle actin expression is associated with epithelial-mesenchymal transition and stem-like properties in hepatocellular carcinoma.

Benzoubir N, Mussini C, Lejamtel C, Dos Santos A, Guillaume C, Desterke C, Samuel D, Bréchot C, Bourgeade MF, Guettier C.

PLoS One. 2015 Jun 25;10(6):e0130559. doi: 10.1371/journal.pone.0130559. eCollection 2015.

14.

Is the Reg3α (HIP/PAP) Protein Really an Obesogenic Factor?

Gonzalez P, Moniaux N, Bréchot C, Faivre J.

J Cell Physiol. 2016 Jan;231(1):1. doi: 10.1002/jcp.25046. No abstract available.

PMID:
26096764
15.

A global biomedical R&D fund and mechanism for innovations of public health importance.

Balasegaram M, Bréchot C, Farrar J, Heymann D, Ganguly N, Khor M, Lévy Y, Matsoso P, Minghui R, Pécoul B, Peilong L, Tanner M, Røttingen JA.

PLoS Med. 2015 May 11;12(5):e1001831. doi: 10.1371/journal.pmed.1001831. eCollection 2015 May. No abstract available.

16.

The Reg3α (HIP/PAP) Lectin Suppresses Extracellular Oxidative Stress in a Murine Model of Acute Liver Failure.

Moniaux N, Darnaud M, Garbin K, Dos Santos A, Guettier C, Samuel D, Amouyal G, Amouyal P, Bréchot C, Faivre J.

PLoS One. 2015 May 4;10(5):e0125584. doi: 10.1371/journal.pone.0125584. eCollection 2015.

17.

Natural variations of copper and sulfur stable isotopes in blood of hepatocellular carcinoma patients.

Balter V, Nogueira da Costa A, Bondanese VP, Jaouen K, Lamboux A, Sangrajrang S, Vincent N, Fourel F, Télouk P, Gigou M, Lécuyer C, Srivatanakul P, Bréchot C, Albarède F, Hainaut P.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):982-5. doi: 10.1073/pnas.1415151112. Epub 2015 Jan 12.

18.

HIP/PAP prevents excitotoxic neuronal death and promotes plasticity.

Haldipur P, Dupuis N, Degos V, Moniaux N, Chhor V, Rasika S, Schwendimann L, le Charpentier T, Rougier E, Amouyal P, Amouyal G, Dournaud P, Bréchot C, El Ghouzzi V, Faivre J, Fleiss B, Mani S, Gressens P.

Ann Clin Transl Neurol. 2014 Oct;1(10):739-54. doi: 10.1002/acn3.127. Epub 2014 Oct 9.

19.

BBMRI-ERIC as a resource for pharmaceutical and life science industries: the development of biobank-based Expert Centres.

van Ommen GJ, Törnwall O, Bréchot C, Dagher G, Galli J, Hveem K, Landegren U, Luchinat C, Metspalu A, Nilsson C, Solesvik OV, Perola M, Litton JE, Zatloukal K.

Eur J Hum Genet. 2015 Jul;23(7):893-900. doi: 10.1038/ejhg.2014.235. Epub 2014 Nov 19.

20.

Public biobanks: calculation and recovery of costs.

Clément B, Yuille M, Zaltoukal K, Wichmann HE, Anton G, Parodi B, Kozera L, Bréchot C, Hofman P, Dagher G; EU-US Expert Group on cost recovery in biobanks.

Sci Transl Med. 2014 Nov 5;6(261):261fs45. doi: 10.1126/scitranslmed.3010444.

PMID:
25378642
21.

Public-private relationships in biobanking: a still underestimated key component of open innovation.

Hofman P, Bréchot C, Zatloukal K, Dagher G, Clément B.

Virchows Arch. 2014 Jan;464(1):3-9. doi: 10.1007/s00428-013-1524-z. Epub 2013 Dec 14. Review.

PMID:
24337181
22.

[Crosstalk between the liver and the gut: role of the microbiota in liver carcinogenesis].

Faivre J, Bréchot C, Moniaux N.

Med Sci (Paris). 2013 Nov;29(11):954-6. doi: 10.1051/medsci/20132911008. Epub 2013 Nov 20. French. No abstract available.

23.

The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells.

Guerrieri F, Piconese S, Lacoste C, Schinzari V, Testoni B, Valogne Y, Gerbal-Chaloin S, Samuel D, Bréchot C, Faivre J, Levrero M.

Cell Death Dis. 2013 Sep 19;4:e807. doi: 10.1038/cddis.2013.302.

24.

HCV core-mediated activation of latent TGF-β via thrombospondin drives the crosstalk between hepatocytes and stromal environment.

Benzoubir N, Lejamtel C, Battaglia S, Testoni B, Benassi B, Gondeau C, Perrin-Cocon L, Desterke C, Thiers V, Samuel D, Levrero M, Bréchot C, Bourgeade MF.

J Hepatol. 2013 Dec;59(6):1160-8. doi: 10.1016/j.jhep.2013.07.036. Epub 2013 Aug 6.

PMID:
23928402
25.

Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG.

Lacoste C, Hervé J, Bou Nader M, Dos Santos A, Moniaux N, Valogne Y, Montjean R, Dorseuil O, Samuel D, Cassio D, Portulano C, Carrasco N, Bréchot C, Faivre J.

Cancer Res. 2012 Nov 1;72(21):5505-15. doi: 10.1158/0008-5472.CAN-12-0516. Epub 2012 Sep 7.

26.

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.

Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Müllhaupt B, Semela D, Dufour JF, Heim MH, Moradpour D, Cerny A, Malinverni R, Hirsch H, Martinetti G, Suppiah V, Stewart G, Booth DR, George J, Casanova JL, Bréchot C, Rice CM, Talal AH, Jacobson IM, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud PY, Abel L; Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium; French ANRS HC EP 26 Genoscan Study Group.

Gastroenterology. 2012 Nov;143(5):1244-1252.e12. doi: 10.1053/j.gastro.2012.07.097. Epub 2012 Jul 27.

27.

An intron-retaining splice variant of human cyclin A2, expressed in adult differentiated tissues, induces a G1/S cell cycle arrest in vitro.

Honda A, Valogne Y, Bou Nader M, Bréchot C, Faivre J.

PLoS One. 2012;7(6):e39249. doi: 10.1371/journal.pone.0039249. Epub 2012 Jun 20.

28.

[HIP/PAP, a new drug for acute liver failure].

Moniaux N, Darnaud M, Dos Santos A, Jamot L, Samuel D, Amouyal P, Amouyal G, Bréchot C, Faivre J.

Med Sci (Paris). 2012 Mar;28(3):239-41. doi: 10.1051/medsci/2012283004. Epub 2012 Apr 6. French. No abstract available.

29.

Prothrombin index slope is an early prognostic marker in patients with severe acute liver diseases.

Nalpas B, Francoz C, Ichaï P, Jamot L, Faivre J, Lemoinne S, Samuel D, Durand F, Bernuau J, Bréchot C, Amouyal P, Amouyal G.

Gut. 2012 Jul;61(7):1098-100. doi: 10.1136/gutjnl-2011-301316. Epub 2011 Oct 24. No abstract available.

PMID:
22027480
30.

Enterotypes of the human gut microbiome.

Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J; MetaHIT Consortium, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P.

Nature. 2011 May 12;473(7346):174-80. doi: 10.1038/nature09944. Epub 2011 Apr 20. Erratum in: Nature. 2011 Jun 30;474(7353):666. Nature. 2014 Feb 27;506(7489):516.

31.

Human hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein cures fas-induced acute liver failure in mice by attenuating free-radical damage in injured livers.

Moniaux N, Song H, Darnaud M, Garbin K, Gigou M, Mitchell C, Samuel D, Jamot L, Amouyal P, Amouyal G, Bréchot C, Faivre J.

Hepatology. 2011 Feb;53(2):618-27. doi: 10.1002/hep.24087. Epub 2010 Dec 17.

PMID:
21274882
32.
33.

Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms.

Brechot C, Kremsdorf D, Soussan P, Pineau P, Dejean A, Paterlini-Brechot P, Tiollais P.

Pathol Biol (Paris). 2010 Aug;58(4):278-87. doi: 10.1016/j.patbio.2010.05.001. Epub 2010 Jul 27. Review.

PMID:
20667665
34.

Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection.

Nalpas B, Lavialle-Meziani R, Plancoulaine S, Jouanguy E, Nalpas A, Munteanu M, Charlotte F, Ranque B, Patin E, Heath S, Fontaine H, Vallet-Pichard A, Pontoire D, Bourlière M, Casanova JL, Lathrop M, Bréchot C, Poynard T, Matsuda F, Pol S, Abel L.

Gut. 2010 Aug;59(8):1120-6. doi: 10.1136/gut.2009.202267. Epub 2010 Jun 29.

PMID:
20587546
35.

Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics.

Dos Santos A, Court M, Thiers V, Sar S, Guettier C, Samuel D, Bréchot C, Garin J, Demaugre F, Masselon CD.

Mol Cell Proteomics. 2010 Sep;9(9):1991-2004. doi: 10.1074/mcp.M110.000026. Epub 2010 May 31.

36.

[Epithelial-mesenchymal transition and hepatocellular carcinoma].

Battaglia S, Benzoubir N, Ghigna MR, Guettier C, Bréchot C, Bourgeade MF.

Ann Pathol. 2009 Nov;29 Spec No 1:S65-6. doi: 10.1016/j.annpat.2009.07.042. Epub 2009 Oct 6. Review. French. No abstract available.

PMID:
19887256
37.

Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition.

Battaglia S, Benzoubir N, Nobilet S, Charneau P, Samuel D, Zignego AL, Atfi A, Bréchot C, Bourgeade MF.

PLoS One. 2009;4(2):e4355. doi: 10.1371/journal.pone.0004355. Epub 2009 Feb 3.

38.

Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter.

Hervé J, Cunha AS, Liu B, Valogne Y, Longuet M, Boisgard R, Brégerie O, Roux J, Guettier C, Calès P, Tavitian B, Samuel D, Clerc J, Bréchot C, Faivre J.

Hum Gene Ther. 2008 Sep;19(9):915-26. doi: 10.1089/hum.2007.153.

PMID:
18759560
39.

Hepatitis C virus core proteins derived from different quasispecies of genotype 1b inhibit the growth of Chang liver cells.

Yan XB, Mei L, Feng X, Wan MR, Chen Z, Pavio N, Brechot C.

World J Gastroenterol. 2008 May 14;14(18):2877-81.

40.

Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.

Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B, Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C, Samuel D.

Gastroenterology. 2008 Jun;134(7):1890-9; quiz 2155. doi: 10.1053/j.gastro.2008.02.064. Epub 2008 Mar 4.

PMID:
18424269
41.

Change in hepatitis C virus genotype in hemodialysis patients after end-of-treatment response to interferon monotherapy--relapse or re-infection?

Arrais TC, Van Dooren S, Vandamme AM, Brechot C, Rimlinger F, Silva AE, Perez RM, Ferraz ML, Thiers V.

J Med Virol. 2008 Jan;80(1):80-6.

PMID:
18041025
42.

Biobanking for Europe.

Yuille M, van Ommen GJ, Bréchot C, Cambon-Thomsen A, Dagher G, Landegren U, Litton JE, Pasterk M, Peltonen L, Taussig M, Wichmann HE, Zatloukal K.

Brief Bioinform. 2008 Jan;9(1):14-24. Epub 2007 Oct 23. Review.

PMID:
17959611
43.

Distinct hepatitis C virus core and F protein quasispecies in tumoral and nontumoral hepatocytes isolated via microdissection.

Sobesky R, Feray C, Rimlinger F, Derian N, Dos Santos A, Roque-Afonso AM, Samuel D, Bréchot C, Thiers V.

Hepatology. 2007 Dec;46(6):1704-12.

PMID:
17935229
44.

Contribution of laser microdissection-based technology to proteomic analysis in hepatocellular carcinoma developing on cirrhosis.

Dos Santos A, Thiers V, Sar S, Derian N, Bensalem N, Yilmaz F, Bralet MP, Ducot B, Bréchot C, Demaugre F.

Proteomics Clin Appl. 2007 Jun;1(6):545-54. doi: 10.1002/prca.200600474. Epub 2007 May 11.

45.

Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.

Liu B, Hervé J, Bioulac-Sage P, Valogne Y, Roux J, Yilmaz F, Boisgard R, Guettier C, Calès P, Tavitian B, Samuel D, Clerc J, Bréchot C, Faivre J.

Gastroenterology. 2007 Apr;132(4):1495-503. Epub 2007 Jan 26.

PMID:
17408651
46.

[Impact of calcium signaling in liver carcinogenesis].

Chami M, Benali NL, Bréchot C, Paterlini-Bréchot P.

Med Sci (Paris). 2007 Feb;23(2):133-5. French. No abstract available.

47.

Mapping of the interacting domains of hepatitis C virus core protein and the double-stranded RNA-activated protein kinase PKR.

Yan XB, Battaglia S, Boucreux D, Chen Z, Brechot C, Pavio N.

Virus Res. 2007 Apr;125(1):79-87. Epub 2007 Jan 30.

PMID:
17267064
48.

The intraflagellar transport component IFT88/polaris is a centrosomal protein regulating G1-S transition in non-ciliated cells.

Robert A, Margall-Ducos G, Guidotti JE, Brégerie O, Celati C, Bréchot C, Desdouets C.

J Cell Sci. 2007 Feb 15;120(Pt 4):628-37. Epub 2007 Jan 30. Erratum in: J Cell Sci. 2007 Mar 1;120(Pt 5):918.

49.

Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice.

Lieu HT, Simon MT, Nguyen-Khoa T, Kebede M, Cortes A, Tebar L, Smith AJ, Bayne R, Hunt SP, Bréchot C, Christa L.

Hepatology. 2006 Dec;44(6):1452-64.

PMID:
17133485
50.

Supplemental Content

Loading ...
Support Center